当前位置:
X-MOL 学术
›
Nat. Commun.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Nature Communications ( IF 14.7 ) Pub Date : 2021-09-16 , DOI: 10.1038/s41467-021-25901-z Carla L Alves 1 , Sidse Ehmsen 1, 2 , Mikkel G Terp 1 , Neil Portman 3, 4 , Martina Tuttolomondo 1 , Odd L Gammelgaard 1 , Monique F Hundebøl 1 , Kamila Kaminska 5 , Lene E Johansen 1 , Martin Bak 6 , Gabriella Honeth 5 , Ana Bosch 5 , Elgene Lim 3, 4 , Henrik J Ditzel 1, 2, 7
中文翻译:
出版商更正:CDK4/6 和 AKT 与内分泌治疗的共同靶向可防止 CDK4/6 抑制剂和内分泌治疗耐药乳腺癌的进展。
更新日期:2021-09-16
Nature Communications ( IF 14.7 ) Pub Date : 2021-09-16 , DOI: 10.1038/s41467-021-25901-z Carla L Alves 1 , Sidse Ehmsen 1, 2 , Mikkel G Terp 1 , Neil Portman 3, 4 , Martina Tuttolomondo 1 , Odd L Gammelgaard 1 , Monique F Hundebøl 1 , Kamila Kaminska 5 , Lene E Johansen 1 , Martin Bak 6 , Gabriella Honeth 5 , Ana Bosch 5 , Elgene Lim 3, 4 , Henrik J Ditzel 1, 2, 7
Affiliation
中文翻译:
出版商更正:CDK4/6 和 AKT 与内分泌治疗的共同靶向可防止 CDK4/6 抑制剂和内分泌治疗耐药乳腺癌的进展。